➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Baxter
Boehringer Ingelheim
Colorcon
AstraZeneca

Last Updated: January 25, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Relacorilant

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Relacorilant?

Relacorilant is an investigational drug.

There have been 11 clinical trials for Relacorilant. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2018.

The most common disease conditions in clinical trials are Cushing Syndrome, Syndrome, and Carcinoma. The leading clinical trial sponsors are Corcept Therapeutics, University of Chicago, and National Cancer Institute (NCI).

There are eleven US patents protecting this investigational drug and eighty-one international patents.

Recent Clinical Trials for Relacorilant
TitleSponsorPhase
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid ProductionCorcept TherapeuticsPhase 1
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal AdenocarcinomaCorcept TherapeuticsPhase 3
Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal AdenomasCorcept TherapeuticsPhase 3

See all Relacorilant clinical trials

Clinical Trial Summary for Relacorilant

Top disease conditions for Relacorilant
Top clinical trial sponsors for Relacorilant

See all Relacorilant clinical trials

US Patents for Relacorilant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Relacorilant   Start Trial Glucocorticoid receptor modulators to treat pancreatic cancer Corcept Therapeutics, Inc. (Menlo Park, CA)   Start Trial
Relacorilant   Start Trial Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome Corcept Therapeutics, Inc. (Menlo Park, CA)   Start Trial
Relacorilant   Start Trial Glucocorticoid receptor modulators to treat cervical cancer Corcept Therapeutics, Inc. (Menlo Park, CA)   Start Trial
Relacorilant   Start Trial Glucocorticoid receptor modulators to treat pancreatic cancer Corcept Therapeutics, Inc. (Menlo Park, CA)   Start Trial
Relacorilant   Start Trial Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators Corcept Therapeutics, Inc. (Menlo Park, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Relacorilant

Drugname Country Document Number Estimated Expiration Related US Patent
Relacorilant Australia AU2017323636 2036-09-09   Start Trial
Relacorilant Brazil BR112019004322 2036-09-09   Start Trial
Relacorilant Canada CA3034114 2036-09-09   Start Trial
Relacorilant China CN109689044 2036-09-09   Start Trial
Relacorilant European Patent Office EP3509584 2036-09-09   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Baxter
Boehringer Ingelheim
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.